ASTRAZENECA PLC secured United States approval for its hypertension pill Baxfendy, which the drugmaker expects to generate $5 billion in peak annual sales. The decision follows the $1.8 billion acquisition of CinCor Pharma in February 2023 to expand the cardiovascular portfolio. It provides a new revenue stream addressing 120 million Americans with uncontrolled high blood pressure despite existing treatments.

A New Mechanism for Uncontrolled Hypertension